SCHEMBL3533573

SCHEMBL3533573

CS(=O)(=O)Nc1cccc(-c2cnc(N)c3c(Br)csc23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 4/20 0.55
BRAF P15056 8/20 0.49
EPHB4 P54760 2/20 0.48
FYN P06241 2/20 0.48
TGFBR1 P36897 1/20 0.48
ACVR1 Q04771 1/20 0.48
TYRO3 Q06418 1/20 0.48
KDR P35968 3/20 0.47
AURKB Q96GD4 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
HTT P42858 1/20 0.46
AURKA O14965 1/20 0.46
DYRK3 O43781 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
ABL1 P00519 1/20 0.46
EGFR P00533 1/20 0.46
INSR P06213 1/20 0.46
CSF1R P07333 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534909 0.86 USP7 (0.48) PTK2EPHB4FYNKDRAURKB
SCHEMBL3576965 0.86 KDR (0.55) PTK2BRAFEPHB4FYNKDR
SCHEMBL3530119 0.83 EPHB4 (0.67) PTK2BRAFEPHB4FYNKDR
SCHEMBL3525217 0.83 BRAF (0.59) BRAFFYNKDRAURKBCYP3A4
SCHEMBL3527121 0.79 KDR (0.77) PTK2BRAFEPHB4FYNKDR
SCHEMBL3530360 0.78 KDR (0.81) PTK2FYNTYRO3KDRAURKB
SCHEMBL5550688 0.78 BRAF (0.49) BRAFEPHB4KDRAURKB
SCHEMBL3534163 0.76 BTK (0.55) BRAFEPHB4ACVR1TYRO3KDR
SCHEMBL3526975 0.76 EPHB4 (0.52) PTK2EPHB4FYNKDRAURKB
SCHEMBL3584761 0.74 KDR (0.51) PTK2EPHB4FYNKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK PTK2 89/4885BRAF 26/4885EPHB4 896/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK PTK2 89/4885BRAF 26/4885EPHB4 896/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK PTK2 89/4885BRAF 26/4885EPHB4 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.